CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA205410 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA205410.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: HEMANGEOL (PROPRANOLOL HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA205410 · Cardiology

High

Hemangeol (propranolol hydrochloride) is an oral solution approved under NDA205410 as a new formulation for an orphan indication, billing through Medicare Part D as a self-administered oral drug. As a

View alert

Audit documentation

Building an audit file that includes FDA-NDA205410?

The Tripwire Audit Pack exports 12 months of Cardiology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Cardiology audit pack — $349One-time purchase · not a subscription